All In Biotech

Drug Trial Radar · NCT04513912

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Double-Blind, Randomized, Parallel-Group Study With Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 757 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

757

Actual

Start

Sep 15, 2020

Primary completion

Oct 3, 2023

Study completion Oct 3, 2023

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Aug 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).

Conditions

  • Depressive Disorder, Major

Interventions

  • SeltorexantDrug

    Participants will receive seltorexant over-encapsulated tablet orally.

  • Matching placebo to SeltorexantDrug

    Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.

  • Quetiapine XRDrug

    Participants will receive quetiapine XR capsule orally.

  • Matching placebo to Quetiapine XRDrug

    Participants will receive placebo capsule matching to quetiapine XR orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved Response (Greater Than or Equal to [>=50] Percent Improvement in Montgomery-Asberg Depression Rating Scale [MADRS] Total Score From Baseline) at Week 26Time frame: Week 26

Locations

175 sites in 15 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • SW Biomedical Research LLC

    Tucson, Arizona

  • Proscience Research Group

    Culver City, California

  • Pharmacology Research Institute

    Encino, California

  • Collaborative NeuroScience Network

    Garden Grove, California

  • Collaborative NeuroScience Network

    Long Beach, California

  • Pharmacology Research Institute

    Los Alamitos, California

  • CalNeuro Research

    Los Angeles, California

  • Pharmacology Research Institute

    Newport Beach, California

  • NRC Research Institute

    Orange, California

  • Pacific Neuropsychiatric Specialists

    Orange, California

  • CNRI-Los Angeles, LLC

    Pico Rivera, California

  • Prospective Research Innovations Inc

    Rancho Cucamonga, California

  • Anderson Clinical Research

    Redlands, California

  • University of California at San Diego

    San Diego, California

  • National Research Institute

    Santa Ana, California

  • CI Trials

    Santa Ana, California

  • CMB Clinical Trials

    Santee, California

  • Schuster Medical Research Institute

    Sherman Oaks, California

  • Pacific Clinical Research Medical Group

    Upland, California

  • Hartford Hospital

    Hartford, Connecticut

  • Moonshine Research Center, Inc

    Doral, Florida

  • Velocity Clinical Research, Hallandale Beach

    Hallandale, Florida

  • Indago Research & Health Center Inc

    Hialeah, Florida

  • New Life Medical Research Center, Inc.

    Hialeah, Florida

  • Amedica Research Institute Inc

    Hialeah, Florida

  • Meridien Research

    Lakeland, Florida

  • Premier Clinical Research

    Miami, Florida

  • Global Medical Institutes

    Miami, Florida

  • Miami Jewish Health System

    Miami, Florida

  • Clinical Neuroscience Solutions

    Orlando, Florida

  • Synexus Research Orlando

    Orlando, Florida

  • University of South Florida

    Tampa, Florida

  • Compass Research LLC-Bioclinica Research

    The Villages, Florida

  • Synexus Clinical Research US Inc

    Atlanta, Georgia

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • iResearch Atlanta LLC

    Decatur, Georgia

  • Psych Atlanta, P.C.

    Marietta, Georgia

  • Chicago Research Center

    Chicago, Illinois

  • Capstone Clinical Research

    Libertyville, Illinois

Showing 40 of 175 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.